Biodistribution and Antitumor Effect of Adriamycin Encapsulated in Long-Circulating Liposomes Containing Amphipathic Polyethylene Glycol or Ganglioside GM1

AbstractBiodistribution and antitumor effect of adriamycin (ADM) encapsulated in liposomes with reduced uptake by reticuloendothelial system (RES) and prolonged circulation time were investigated in mice. Two different types of long-circulating liposomes, ganglioside GMI (GMl)/distearoyl phosphatidyl choline (DSPC) /cholesterol (CH) (0.13:1:1, m/m) and amphipathic polyethylene glycol (PEG)/DSPC/CH (0.13:1:1, m/m) were used. They were sized to 180-200 nm in mean diameter. In the case of amphipathic PEG, distearoyl phosphatidylethanolamine (DSPE) derivatives of PEG with various molecular weight (1000-12000 in mean molecular weight) were used. ADM was encapsulated by transmembrane pH gradient method. GM~DSPC /CH

[1]  K. Maruyama,et al.  Enhanced delivery of doxorubicin to tumor by long-circulating thermosensitive liposomes and local hyperthermia. , 1993, Biochimica et biophysica acta.

[2]  K. Maruyama,et al.  Prolonged circulation time in vivo of large unilamellar liposomes composed of distearoyl phosphatidylcholine and cholesterol containing amphipathic poly(ethylene glycol). , 1992, Biochimica et biophysica acta.

[3]  T. Allen,et al.  Stealth liposomes: an improved sustained release system for 1-beta-D-arabinofuranosylcytosine. , 1992, Cancer research.

[4]  A. Gabizon.  Selective tumor localization and improved therapeutic index of anthracyclines encapsulated in long-circulating liposomes. , 1992, Cancer research.

[5]  A. Gabizon,et al.  Sterically stabilized liposomes: improvements in pharmacokinetics and antitumor therapeutic efficacy. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[6]  T M Allen,et al.  Liposomes containing synthetic lipid derivatives of poly(ethylene glycol) show prolonged circulation half-lives in vivo. , 1991, Biochimica et biophysica acta.

[7]  K. Maruyama,et al.  Effect of molecular weight in amphipathic polyethyleneglycol on prolonging the circulation time of large unilamellar liposomes. , 1991, Chemical & pharmaceutical bulletin.

[8]  V. Torchilin,et al.  Activity of amphipathic poly(ethylene glycol) 5000 to prolong the circulation time of liposomes depends on the liposome size and is unfavorable for immunoliposome binding to target. , 1991, Biochimica et biophysica acta.

[9]  G Gregoriadis,et al.  Influence of surface hydrophilicity of liposomes on their interaction with plasma protein and clearance from the circulation: studies with poly(ethylene glycol)-coated vesicles. , 1991, Biochimica et biophysica acta.

[10]  K. Maruyama,et al.  Polyethyleneglycols effectively increase the liposome concentration in blood circulation. , 1991 .

[11]  G Blume,et al.  Liposomes for the sustained drug release in vivo. , 1990, Biochimica et biophysica acta.

[12]  A. Gabizon,et al.  Effect of liposome composition and other factors on the targeting of liposomes to experimental tumors: biodistribution and imaging studies. , 1990, Cancer research.

[13]  Kazuo Maruyama,et al.  Amphipathic polyethyleneglycols effectively prolong the circulation time of liposomes , 1990, FEBS letters.

[14]  M. Bally,et al.  Liposomes with entrapped doxorubicin exhibit extended blood residence times. , 1990, Biochimica et biophysica acta.

[15]  M. Bally,et al.  Influence of vesicle size, lipid composition, and drug-to-lipid ratio on the biological activity of liposomal doxorubicin in mice. , 1989, Cancer research.

[16]  T. Allen,et al.  Liposomes with prolonged circulation times: factors affecting uptake by reticuloendothelial and other tissues. , 1989, Biochimica et biophysica acta.

[17]  Y. Barenholz,et al.  Separation of liposome-associated doxorubicin from non-liposome-associated doxorubicin in human plasma: implications for pharmacokinetic studies. , 1989, Biochimica et biophysica acta.

[18]  A. Gabizon,et al.  Liposome formulations with prolonged circulation time in blood and enhanced uptake by tumors. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[19]  T M Allen,et al.  Large unilamellar liposomes with low uptake into the reticuloendothelial system , 1987, FEBS letters.

[20]  Y. Barenholz,et al.  Comparative long-term study of the toxicities of free and liposome-associated doxorubicin in mice after intravenous administration. , 1986, Journal of the National Cancer Institute.

[21]  M. Bally,et al.  Uptake of adriamycin into large unilamellar vesicles in response to a pH gradient. , 1986, Biochimica et biophysica acta.

[22]  M. Bally,et al.  Uptake of antineoplastic agents into large unilamellar vesicles in response to a membrane potential. , 1985, Biochimica et biophysica acta.

[23]  P. Cullis,et al.  125I labelled inulin: a convenient marker for deposition of liposomal contents in vivo. , 1984, Biochemical and biophysical research communications.

[24]  J. Weinstein.  Liposomes as drug carriers in cancer therapy. , 1984, Cancer treatment reports.

[25]  Y. Barenholz,et al.  Liposomes as in vivo carriers of adriamycin: reduced cardiac uptake and preserved antitumor activity in mice. , 1982, Cancer research.

[26]  C. Bucana,et al.  Analysis of the fate of systemically administered liposomes and implications for their use in drug delivery. , 1982, Cancer research.

[27]  F. Szoka,et al.  Characterization, toxicity and therapeutic efficacy of adriamycin encapsulated in liposomes. , 1982, European journal of cancer & clinical oncology.

[28]  R. Ozols,et al.  The anthracycline antineoplastic drugs. , 1981, The New England journal of medicine.

[29]  J. C. Robbins,et al.  Modified in vivo behavior of liposomes containing synthetic glycolipids. , 1981, Biochimica et biophysica acta.

[30]  T Nakagawa,et al.  A pharmacokinetic analysis program (multi) for microcomputer. , 1981, Journal of pharmacobio-dynamics.

[31]  B. Sikic,et al.  Liposomal protection of adriamycin-induced cardiotoxicity in mice. , 1980, Cancer research.

[32]  F. Szoka,et al.  Procedure for preparation of liposomes with large internal aqueous space and high capture by reverse-phase evaporation. , 1978, Proceedings of the National Academy of Sciences of the United States of America.

[33]  J. Holland,et al.  Therapeutic effect and toxicity of adriamycin in patients with neoplastic disease , 1971, Cancer.

[34]  A. Moore,et al.  Tissue distribution and disposition of daunomycin (NCS-82151) in mice: fluorometric and isotopic methods. , 1970, Cancer chemotherapy reports.

[35]  G. R. Bartlett.  Phosphorus assay in column chromatography. , 1959, The Journal of biological chemistry.